Shirole, N. H. & Kaelin, W. G. von-Hippel Lindau and hypoxia-inducible factor at the center of renal cell carcinoma biology. Hematol. Oncol. Clin. North Am. 37, 809–825 (2023).

Article  PubMed  PubMed Central  Google Scholar 

US Food and Drug Administration. FDA approves belzutifan for cancers associated with von Hippel-Lindau disease. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease (2021).

US Food and Drug Administration. FDA approves belzutifan for advanced renal cell carcinoma. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-advanced-renal-cell-carcinoma (2023).

US Food and Drug Administration. FDA approves belzutifan for pheochromocytoma or paraganglioma. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma (2025).

Bao, X. et al. The crosstalk between HIFs and mitochondrial dysfunctions in cancer development. Cell Death Dis. 12, 215 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaelin, W. G. The VHL tumor suppressor gene: insights into oxygen sensing and cancer. Trans. Am. Clin. Climatol. Assoc. 128, 298–307 (2017).

PubMed  PubMed Central  Google Scholar 

Tian, H., McKnight, S. L. & Russell, D. W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11, 72–82 (1997).

Article  CAS  PubMed  Google Scholar 

Erbel, P. J. A., Card, P. B., Karakuzu, O., Bruick, R. K. & Gardner, K. H. Structural basis for PAS domain heterodimerization in the basic helix–loop–helix-PAS transcription factor hypoxia-inducible factor. Proc. Natl Acad. Sci. USA 100, 15504–15509 (2003).

Article  CAS  PubMed  PubMed Central  Google Scholar 

To, K. K. W. & Huang, L. E. Suppression of hypoxia-inducible factor 1α (HIF-1α) transcriptional activity by the HIF prolyl hydroxylase EGLN1. J. Biol. Chem. 280, 38102–38107 (2005).

Article  CAS  PubMed  Google Scholar 

Erez, N. et al. Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1α activation and inhibits tumor growth. Cancer Res. 63, 8777–8783 (2003).

CAS  PubMed  Google Scholar 

Kaelin, W. G. Proline hydroxylation and gene expression. Annu. Rev. Biochem. 74, 115–128 (2005).

Article  CAS  PubMed  Google Scholar 

Hon, W.-C. et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417, 975–978 (2002).

Article  CAS  PubMed  Google Scholar 

Kaluz, S., Kaluzová, M. & Stanbridge, E. J. Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. Clinica Chim. Acta 395, 6–13 (2008).

Article  CAS  Google Scholar 

Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16, 4604–4613 (1996).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, G. L. & Semenza, G. L. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 268, 21513–21518 (1993).

Article  CAS  PubMed  Google Scholar 

Ebert, B. L., Firth, J. D. & Ratcliffe, P. J. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J. Biol. Chem. 270, 29083–29089 (1995).

Article  CAS  PubMed  Google Scholar 

Semenza, G. L., Roth, P. H., Fang, H. M. & Wang, G. L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269, 23757–23763 (1994).

Article  CAS  PubMed  Google Scholar 

Carroll, V. A. & Ashcroft, M. Role of hypoxia-inducible factor (HIF)-1α versus HIF-2α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 66, 6264–6270 (2006).

Article  CAS  PubMed  Google Scholar 

Piret, J.-P. et al. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J. Biol. Chem. 280, 9336–9344 (2005).

Article  CAS  PubMed  Google Scholar 

Bindra, R. S., Vasselli, J. R., Stearman, R., Linehan, W. M. & Klausner, R. D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62, 3014–3019 (2002).

CAS  PubMed  Google Scholar 

Bratslavsky, G., Sudarshan, S., Neckers, L. & Linehan, W. M. Pseudohypoxic pathways in renal cell carcinoma. Clin. Cancer Res. 13, 4667–4671 (2007).

Article  CAS  PubMed  Google Scholar 

Friedrich, C. A. Von Hippel-Lindau syndrome. Cancer 86, 2478–2482 (1999).

Article  CAS  PubMed  Google Scholar 

Banks, R. E. et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 66, 2000–2011 (2006).

Article  CAS  PubMed  Google Scholar 

Creighton, C. J. et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).

Article  CAS  Google Scholar 

Krieg, M. et al. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19, 5435–5443 (2000).

Article  CAS  PubMed  Google Scholar 

Kaelin, W. G. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673–682 (2002).

Article  CAS  PubMed  Google Scholar 

Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G. & Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595–10599 (1996).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Selak, M. A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7, 77–85 (2005).

Article  CAS  PubMed  Google Scholar 

Pollard, P. J. et al. Targeted inactivation of Fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 11, 311–319 (2007).

Article  CAS  PubMed  Google Scholar 

Cascón, A. et al. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. J. Natl Cancer Inst. 107, djv053 (2015).

Article  PubMed  Google Scholar 

Kaelin, W. G. The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem. Biophys. Res. Commun. 338, 627–638 (2005).

Article  CAS  PubMed  Google Scholar 

Neumann, H. P. H., Young, W. F. & Eng, C. Pheochromocytoma and paraganglioma. N. Engl. J. Med. 381, 552–565 (2019).

Article  CAS  PubMed  Google Scholar 

Pollard, P. J. et al. Accumulation of krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231–2239 (2005).

Article  CAS  PubMed  Google Scholar 

Menko, F. H. et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam. Cancer 13, 637–644 (2014).

Article